ZyVersa Therapeutics Inc. • ZVSA

Capital at risk.

About ZyVersa Therapeutics Inc.
Ticker
info
ZVSA
Trading on
info
NASDAQ
ISIN
info
US98987D3008
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Stephen C. Glover
Headquarters
info
2200 N. Commerce Parkway, Weston, FL, United States, 33326
Employees
info
7
Website
info
zyversa.com
ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company that develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. The company has a license agreement with L&F Research LLC, and InflamaCORE, LLC. ZyVersa Therapeutics, Inc. was founded in 2014 and is based in Weston, Florida.
Metrics
BasicAdvanced
Market cap
info
$1.1M
P/E ratio
info
-
EPS
info
-$3.32
Dividend Yield
info
0.00%
Beta
info
0.83
Forward P/E ratio
info
0
EBIDTA
info
$-7.6M
Ex dividend date
info
-
Price & volume
Market cap
info
$1.1M
Average daily volume
info
0M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
0
PEG ratio
info
-
Trailing P/E
info
0
Price to sales
info
0
Price to book
info
0.21
Earnings
EPS
info
-$3.32
EPS estimate (current quarter)
info
$0.00
EPS estimate (next quarter)
info
$0.00
EBITDA
info
$-7.6M
Revenues (TTM)
info
$0M
Revenues per share (TTM)
info
$0.00
Technicals
Beta
info
0.83
52-week High
info
$1.95
52-week Low
info
$0.11
50-day moving average
info
$0.15
200-day moving average
info
$0.45
Short ratio
info
0.25
Short %
info
7.38%
Management effectiveness
ROE (TTM)
info
-112.65%
ROA (TTM)
info
-46.30%
Profit margin
info
0.00%
Gross profit margin
info
$0M
Operating margin
info
0.00%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
0.00%
Share stats
Outstanding Shares
info
8.1M
Float
info
7.7M
Insiders %
info
0.03%
Institutions %
info
5.15%
Analyst Insights & forecasts
info

100% Buy

0% Hold

0% Sell

Based on information from 1 analysts.

Average price target

info
$20.00
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$1.31
-
-
Q4 • 24Beat
-$0.73
-$0.40
-82.50%
Q1 • 25Missed
-$0.46
-$0.40
-15.00%
Q2 • 25Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$0M
$-2.2M
-∞%
Q2 • 25
$0M
$-19.8B
-∞%
Q3 • 25
NaN%
895,545.40%
NaN%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$19.6M
$13.5M
68.94%
Q2 • 25
$1M
$12.8M
1,227.18%
Q3 • 25
-94.70%
-5.73%
1,679.97%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-1.52B
-
$-17.7M
$-1.52B
Q2 • 25
$-1.41B
-
$1.86B
$-1.41B
Q3 • 25
-7.55%
-
-10,613.62%
-7.55%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a ZyVersa Therapeutics Inc. share?
Collapse

ZyVersa Therapeutics Inc. shares are currently traded for undefined per share.

How many shares does ZyVersa Therapeutics Inc. have?
Collapse

ZyVersa Therapeutics Inc. currently has 8.1M shares.

Does ZyVersa Therapeutics Inc. pay dividends?
Collapse

No, ZyVersa Therapeutics Inc. doesn't pay dividends.

What is ZyVersa Therapeutics Inc. 52 week high?
Collapse

ZyVersa Therapeutics Inc. 52 week high is $1.95.

What is ZyVersa Therapeutics Inc. 52 week low?
Collapse

ZyVersa Therapeutics Inc. 52 week low is $0.11.

What is the 200-day moving average of ZyVersa Therapeutics Inc.?
Collapse

ZyVersa Therapeutics Inc. 200-day moving average is $0.45.

Who is ZyVersa Therapeutics Inc. CEO?
Collapse

The CEO of ZyVersa Therapeutics Inc. is Stephen C. Glover.

How many employees ZyVersa Therapeutics Inc. has?
Collapse

ZyVersa Therapeutics Inc. has 7 employees.

What is the market cap of ZyVersa Therapeutics Inc.?
Collapse

The market cap of ZyVersa Therapeutics Inc. is $1.1M.

What is the P/E of ZyVersa Therapeutics Inc.?
Collapse

The current P/E of ZyVersa Therapeutics Inc. is null.

What is the EPS of ZyVersa Therapeutics Inc.?
Collapse

The EPS of ZyVersa Therapeutics Inc. is -$3.32.

What is the PEG Ratio of ZyVersa Therapeutics Inc.?
Collapse

The PEG Ratio of ZyVersa Therapeutics Inc. is null.

What do analysts say about ZyVersa Therapeutics Inc.?
Collapse

According to the analysts ZyVersa Therapeutics Inc. is considered a buy.